Inhibitor Therapeutics (INTI) Change in Accured Expenses (2012 - 2026)
Inhibitor Therapeutics' Change in Accured Expenses was -$208,216 in Q2 2026, compared with $45,249 a year earlier.
Powered by 
Analysis
Inhibitor Therapeutics (INTI) Change in Accured Expenses (2012 - 2026) Analysis & Trends
On a trailing twelve-month basis, Inhibitor Therapeutics' Change in Accured Expenses was $31,149 through Jun 30, 2026, down 60.3% year-over-year; for FY2025, it was $28,502, down 35.9% from FY2024.
- In earlier years, Change in Accured Expenses was $44,454 in FY2024 (-88.8%), $397,382 in FY2023 (+188.3%), $137,829 in FY2022 (+158.8%) and $53,267 in FY2021.
- Quarterly Change in Accured Expenses has moved between -$640,893 (Q1 2025) and $678,042 (Q4 2025) over five years.
- The best year-over-year quarter for Change in Accured Expenses over five years was Q4 2023 (growth of 757.5%); the worst was Q3 2024 (a decline of 92.0%).
- Per Business Quant data, INTI's Change in Accured Expenses in the three quarters before Q2 2026 was -$384,781 (Q1 2026), $678,042 (Q4 2025) and -$53,896 (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Accured Exp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | - |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 2.96 Bn |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | 1.20 Bn |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | - |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | -251.00 Mn |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | - |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 901.00 Mn |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | 338.00 Mn |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | - |
| 10 | Inhibitor Therapeutics | 17.38 Mn | 17.38 Mn | - | -208,216.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -208,216.00 |
| Mar 31, 2026 | -384,781.00 |
| Dec 31, 2025 | 678,042.00 |
| Sep 30, 2025 | -53,896.00 |
| Jun 30, 2025 | 45,249.00 |
| Mar 31, 2025 | -640,893.00 |
| Dec 31, 2024 | 665,059.00 |
| Sep 30, 2024 | 9,032.00 |
| Jun 30, 2024 | -120,323.00 |
| Mar 31, 2024 | -509,314.00 |
| Dec 31, 2023 | 508,724.00 |
| Sep 30, 2023 | 112,581.00 |
| Jun 30, 2023 | -34,584.00 |
| Mar 31, 2023 | -189,339.00 |
| Dec 31, 2022 | 59,327.00 |
| Sep 30, 2022 | 22,292.00 |
| Jun 30, 2022 | 4,941.00 |
| Mar 31, 2022 | 51,269.00 |
| Dec 31, 2021 | -173.00 |
| Sep 30, 2021 | 27,049.00 |
API Access
Inhibitor Therapeutics Change in Accured Expenses API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=change-in-accured-expenses&ticker=INTI&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "change-in-accured-expenses", "ticker": "INTI", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=change-in-accured-expenses&ticker=INTI&period=max&api_key=YOUR_API_KEY");
const data = await res.json();